ReviewNature reviews. Endocrinology2025
Advances in the management of hyperglycaemia and diabetes mellitus during hospitalization.
Review in Nature reviews. Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.Cardiovascular diabetology · 2026Trial
- Diabetes Management Strategies in Intensive Care Settings.The Medical clinics of North America · 2026Review
- Low-value glucose monitoring in noncritically ill hospitalized patients.Journal of hospital medicine · 2026Article
- Risk Factors for Mortality in Critically Ill Patients with Diabetes Admitted to the ICU: A Single-Center Retrospective Observational Study.Journal of clinical medicine · 2026Article
- A Photothermally Triggered Nanoplatform for Multidimensional Antibacterial Therapy and Accelerated Healing of Infected Wounds.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus, which affects over 537 million people worldwide, considerably increases the risk of emergency room visits and admissions to hospital. Inpatient hyperglycaemia in patients with or without diabetes mellitus is associated with higher rates of complications, extended hospital stays and increased mortality when compared with patients with normoglycaemia. The American Diabetes Association recommends a target range of 5.6-10.0 mmol/l (100-180 mg/dl) for levels of glucose in the blood of patients in intensive care units (ICUs), as well as in general medicine and surgery. Insulin therapy remains the cornerstone of managing inpatient hyperglycaemia, with intravenous insulin preferred in ICU and basal-bolus regimens favoured in non-ICU settings. While bedside capillary blood glucose monitoring is standard for adjusting insulin doses, continuous glucose monitoring provides a more comprehensive glycaemic assessment and enhances the prevention of hypoglycaemia in high-risk hospitalized patients. This Review outlines the latest evidence in managing diabetes mellitus and hyperglycaemia within hospitals.
Indexed as
Identifiers
40760269What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.